THE LANCET CHILD & ADOL. HEALTH: Study suggests need for improved support for transgender and non-binary young people after hospitalization
Peer-reviewed / Observational study / People
- First nationally representative study estimates that, among young people who have been hospitalised in the USA, those with a gender dysphoria diagnosis are four to five times more likely to have been admitted for a suicide attempt or self-harm than those without gender dysphoria.
- The authors call for reducing discrimination towards transgender and non-binary youth, providing them with care that is gender-affirming when they are hospitalised, particularly if admitted for suicide or self-harm, and then linking them to ongoing gender-affirming medical and mental health services.
Among hospitalised young people in the United States, 66% of those with a gender dysphoria diagnosis were admitted for suicide attempts or self-harm in 2019, compared to 5% without gender dysphoria, according to a study published in The Lancet Child & Adolescent Health.
The study looked at over 2 million instances of young people (6 to 20 years old) hospitalised for any reason and determined how many of those hospitalisations were related to suicide or self-harm attempts, for those with and those without a gender dysphoria diagnosis. The authors emphasise that young people who have been hospitalised are likely to be at higher risk of suicidal thoughts and self-harm than young people in general.
Transgender and non-binary young people experience discrimination that has been linked with suicidal thoughts or suicide attempts and self-harm in prior studies surveying outpatient populations, but existing evidence on how many individuals end up hospitalized is limited. This study is the first to use a large nationally representative inpatient database to understand the relationship between gender dysphoria and attempted suicide and self-harm.
Dr Nadir Yehya, of Children’s Hospital of Philadelphia (CHOP), USA, says, “Sadly, our study confirms existing evidence that suicide and self-harm attempts are more common among transgender or non-binary young people. To help this vulnerable group and prevent adverse outcomes, we need to reduce discrimination. As healthcare providers, we have a unique opportunity to do this by providing care that is more gender-affirming to these children when they are hospitalised. This includes addressing patients using their affirmed names and pronouns, linking them to gender-affirming medical care and social support services, and implementing targeted follow-up services for self-harm.” [1]
The study used the nationally representative Kids’ Inpatient Database (KID) in the two most recent available years, 2016 and 2019. It included 80% of all paediatric discharges in the USA, amounting to over 3 million patients in both years. To identify transgender or non-binary youth, the authors searched for any patients who had been diagnosed with gender dysphoria, or any other label that referred to gender dysphoria. Then, they estimated the number of children who had been hospitalised for suicide attempts, self-harm, and a combination of suicide attempts and self-harm, comparing rates in young people with and without gender dysphoria. Additionally, they investigated differences in the prevalence of gender dysphoria according to certain characteristics, including race, type of medical insurance, and the median income in the patient’s area of residence.
Hospitalised young people with gender dysphoria had a higher prevalence of suicide attempts compared to those without gender dysphoria in both 2016 (36% versus 5%) and 2019 (55% versus 4%). Similarly, prevalence of self-harm was higher in hospitalised young people with gender dysphoria in both years (13% versus 1% in 2016 and 15% versus 1% in 2019).
Looking at both combined, hospitalised young people with gender dysphoria were four to five times more likely to experience self-harm or suicide attempts compared to those without gender dysphoria. In 2016, 41% of hospitalised young people with gender dysphoria experienced suicide attempts or self-harm compared to 6% without; in 2019 that rose to 66% versus 5%. See table 1 for numbers of individuals.
Although the overall proportion of young people with gender dysphoria remained low, it increased significantly from 2016 (0.16%) to 2019 (0.48%). The authors say this is likely due to increasing societal understanding and acceptance of diverse gender identities as well as increased access to gender-affirming medical and mental health services.
Young people who were Black, Hispanic or Latinx, or other minority ethnic and racial groups, publicly insured, or from low-income households were less likely to be diagnosed with gender dysphoria. The authors say that this does not necessarily mean that gender dysphoria is less common among these groups. It may reflect inequities in access to gender-affirming care, or heightened discrimination in certain settings, which make young people from economically disadvantaged or racial minority backgrounds less likely to be diagnosed.
Those with a gender dysphoria diagnosis were also less likely to be from the South in the USA or from rural hospitals. The authors say these regional inequities raise concerns about increased levels of discrimination within and outside of healthcare settings in certain locations, which might be preventing young people from self-identifying. It may also mean that healthcare providers in Southern or rural hospitals are less well equipped to provide gender-affirming care. This highlights the impact that regional- and state-level culture and policy can have on determining health outcomes.
The authors note some limitations of their study. It relied on formal diagnoses of gender dysphoria to identify transgender and non-binary youth, which could have biased the estimates in various ways. For example, not all transgender and non-binary young people experience gender dysphoria, which could have led to an underestimation in the size of this group. In addition, some transgender and non-binary youth might not be formally diagnosed with gender dysphoria due to lack of access to a provider who would make the diagnosis. Nonetheless, the authors say this was the most effective way to identify transgender and non-binary youth using this large national dataset and emphasise that their results are consistent with previously reported high rates of suicidal ideation among transgender and non-binary young people.
NOTES TO EDITORS
This study was funded by National Institutes of Health (NIH). It was conducted by researchers from Children's Hospital of Philadelphia, USA.
[1] Quote direct from author and cannot be found in the text of the Article.
The labels have been added to this press release as part of a project run by the Academy of Medical Sciences seeking to improve the communication of evidence. For more information, please see: http://www.sciencemediacentre.org/wp-content/uploads/2018/01/AMS-press-release-labelling-system-GUIDANCE.pdf if you have any questions or feedback, please contact The Lancet press office pressoffice@lancet.com
If you are reporting on this study, please consider including a link to information and support for your readers. In the USA, the National Suicide Prevention Lifeline can be contacted on 1-800-273-TALK (8255) or visit https://suicidepreventionlifeline.org/. In the UK, the number is 116 123, or email: jo@samaritans.org or visit www.samaritans.org For those outside the USA and UK, there is http://www.befrienders.org/ and https://findahelpline.com/.
IF YOU WISH TO PROVIDE A LINK FOR YOUR READERS, PLEASE USE THE FOLLOWING, WHICH WILL GO LIVE AT THE TIME THE EMBARGO LIFTS: https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(22)00280-2/fulltext
JOURNAL
The Lancet Child & Adolescent Health
METHOD OF RESEARCH
Observational study
SUBJECT OF RESEARCH
People
ARTICLE TITLE
Prevalence of gender dysphoria and suicidality and self-harm in a national database of paediatric inpatients in the USA: a population-based, serial cross-sectional study
ARTICLE PUBLICATION DATE
16-Nov-2022
COI STATEMENT
NY reports funding from Pfizer, outside of the scope of this manuscript. All other authors declare no competing interests.
No comments:
Post a Comment